Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors.
about
Function of UDP-glucuronosyltransferase 2B17 (UGT2B17) is involved in endometrial cancerA potential role for human UDP-glucuronosyltransferase 1A4 promoter single nucleotide polymorphisms in the pharmacogenomics of tamoxifen and its derivativesIn vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics.Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.Accurate prediction of glucuronidation of structurally diverse phenolics by human UGT1A9 using combined experimental and in silico approaches.Role of human UDP-glucuronosyltransferases in the biotransformation of the triazoloacridinone and imidazoacridinone antitumor agents C-1305 and C-1311: highly selective substrates for UGT1A10Potential role of UGT1A4 promoter SNPs in anastrozole pharmacogenomicsAromatase inhibitors: prediction of response and nature of resistance.Pharmacogenomics of third-generation aromatase inhibitors.Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer.Influence of multidrug resistance and drug transport proteins on chemotherapy drug metabolism.The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors.Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters.Molecular basis of aromatase inhibitor associated arthralgia: known and potential candidate genes and associated biomarkers.Simultaneous quantitative analysis of letrozole, its carbinol metabolite, and carbinol glucuronide in human plasma by LC-MS/MS.
P2860
Q34094975-B6DCEAEC-9708-476B-9EBF-53CDB3D2E235Q34125047-A6D88FB0-E977-45DC-984B-356A3ED66434Q34457429-EDC2DA7A-5E51-4E8F-9D8F-F86D832549CDQ34793489-EB067FF0-FF74-42FC-905C-4A646C255153Q35008045-85E540AE-BF1D-4A77-9C01-9CB1A0183F2EQ36132276-C5D3A7FB-E385-4D00-B2E1-A8E80DBC5AADQ36174250-B4E02145-3F54-419C-AD9E-EEC515357BCBQ36717159-53DE84EC-46BB-4075-A70F-A1152A25892EQ37760220-1FD470EC-BE8F-48CA-8992-272B60854F1EQ38010777-8C4877CD-20DC-4449-90E4-530BEB422F40Q38103593-0466A952-9C4B-4ED2-8348-3B1A434B7515Q38402177-0BDD1C8E-33C5-462C-9BD5-F4C98FBB4FC8Q38851505-472CE61D-5FA6-4D62-BBFF-A061E0D1AB3AQ38869922-E99C7129-FDB7-4064-8DC5-03B025670C10Q38956073-0CFBFA9A-7F2D-4089-8389-C3E35C3E14A6Q39647911-B7E2EA88-53EF-4C08-B053-1AC33A63514B
P2860
Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Potential role of UGT pharmaco ...... ifen and aromatase inhibitors.
@ast
Potential role of UGT pharmaco ...... ifen and aromatase inhibitors.
@en
Potential role of UGT pharmaco ...... ifen and aromatase inhibitors.
@nl
type
label
Potential role of UGT pharmaco ...... ifen and aromatase inhibitors.
@ast
Potential role of UGT pharmaco ...... ifen and aromatase inhibitors.
@en
Potential role of UGT pharmaco ...... ifen and aromatase inhibitors.
@nl
prefLabel
Potential role of UGT pharmaco ...... ifen and aromatase inhibitors.
@ast
Potential role of UGT pharmaco ...... ifen and aromatase inhibitors.
@en
Potential role of UGT pharmaco ...... ifen and aromatase inhibitors.
@nl
P2860
P1476
Potential role of UGT pharmaco ...... ifen and aromatase inhibitors.
@en
P2093
Dongxiao Sun
Philip Lazarus
P2860
P304
P356
10.3109/03602530903208652
P407
P577
2010-02-01T00:00:00Z